scholarly journals 917 Phase 1b trial of first-line bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, plus chemotherapy with or without bevacizumab in cervical cancer

2021 ◽  
Author(s):  
A Oaknin ◽  
M Gil-Martin ◽  
E Diver ◽  
G Jehl ◽  
SA Gleicher ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Fusion Protein ◽  
Protein Targeting ◽  
First Line ◽  
Phase 1B ◽  
Bifunctional Fusion Protein

Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-β and PD-L1.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 9017-9017 ◽  
Author(s):  
Luis G. Paz-Ares ◽  
Tae Min Kim ◽  
David Vicente Baz ◽  
Enriqueta Felip ◽  
Dae Ho Lee ◽  
...  
Keyword(s):  
Fusion Protein ◽  
Protein Targeting ◽  
Second Line ◽  
Bifunctional Fusion Protein

Selection of the recommended phase 2 dose (RP2D) for M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-β and PD-L1.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 2566-2566 ◽  
Author(s):  
Yulia Vugmeyster ◽  
Justin Wilkins ◽  
Eleanor Harrison-Moench ◽  
Wanping Geng ◽  
Andre Koenig ◽  
...  
Keyword(s):  
Fusion Protein ◽  
Protein Targeting ◽  
Phase 2 ◽  
Bifunctional Fusion Protein ◽  
Selection Of
Sign in / Sign up

Export Citation Format

Share Document